Merck & Company (MRK)
NYSE:MRK
Want to see MRK full AI Analyst Report?
MRK Stock Chart & Stats
$119.07
-$1.54(-1.52%)
At close: 4:00 PM EST
$119.07
-$1.54(-1.52%)
Day’s Range― - ―
52-Week Range$73.31 - $125.14
Previous CloseN/A
Volume3.30M
Average Volume (3M)9.42M
Market Cap
$269.66B
Enterprise Value$310.18B
Total Cash (Recent Filing)$14.56B
Total Debt (Recent Filing)$50.53B
Price to Earnings (P/E)14.5
Beta0.47
Next Earnings
Aug 04, 2026EPS Estimate
2.08Next Dividend Ex-DateN/A
Dividend Yield3.12%
Share Statistics
EPS (TTM)-1.28
Shares Outstanding2,469,879,200
10 Day Avg. Volume9,797,459
30 Day Avg. Volume9,416,709
Financial Highlights & Ratios
PEG Ratio1.88
Price to Book (P/B)5.02
Price to Sales (P/S)4.06
P/FCF Ratio21.35
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue4.77
Enterprise Value/Gross Profit5.85
Enterprise Value/Ebitda11.79
Forecast
1Y Price Target
$136.50Price Target Upside14.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
EPS Forecast (FY)5.1
Revenue Forecast (FY)$66.58B
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentCADENCE met its primary endpoint with meaningful improvements in pulmonary vascular resistance and walking distance and showed no increase in bleeding despite widespread anticoagulant use, supporting advancement to a registrational Phase 3 trial.
HIV Franchise ExpansionLate‑stage oral and long‑acting HIV programs that offer weekly dosing and a monthly prevention option present differentiated clinical value and could expand the company's HIV franchise if approved.
M&A And PipelineAcquisition of TERN adds a chronic myeloid leukemia asset that demonstrated durable responses, lowering late‑stage development risk and strengthening Merck's oncology pipeline.
Bears Say
Commercial And Regulatory RiskLow diagnosis rates for the target condition and ongoing discussions with regulators about Phase 3 design could limit patient identification and create execution risk for future market uptake, while strong competition in HIV may pressure adoption of new entrants.
Dosing UncertaintyAn inverse dose response in CADENCE, where the higher dose underperformed the lower dose, raises questions about optimal dosing and increases the risk that Phase 3 testing may not replicate Phase 2 benefits.
Trial InterpretabilityHeavy use of background heart failure therapies and anticoagulants in the trial population, combined with inconsistent secondary endpoint results, complicates interpretation of efficacy and could undermine confidence in the clinical benefit.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $125.14 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $269.66B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Aug 04, 2026 which is in 94 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Apr 30, 2026. The company reported -$1.28 earnings per share for the quarter, beating the consensus estimate of -$1.474 by $0.194.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.85 which represents an annual dividend yield of 3.12%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.08.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,469,879,200 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of -$1.28 in its last earnings report, beating expectations of -$1.474. Following the earnings report the stock price went down -1.595%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$136.50 (14.64% Upside)
$136.50 (14.64% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 88%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $40.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call mixed strong commercial and pipeline execution with near-term financial and clinical headwinds. Merck reported solid Q1 revenue growth (+5% YoY; $16.3B), robust KEYTRUDA momentum (+8%, $8.0B), notable product and regulatory milestones (IDVYNSO approval, priority reviews for I-DXd and multiple WELIREG filings), accelerating new-product launches and AI partnerships, and raised/narrowed 2026 guidance. Offsetting these positives were a very large one-time $9B Cidara charge that drove a GAAP loss and distorted tax rate, an expected one-time R&D impact from the proposed Terns deal (~$5.8B), meaningful declines in GARDASIL (-22%), a failed LITESPARK-012 readout, and several near-term reimbursement/seasonality headwinds for specific products (ENFLONSIA, OHTUVAYRE). Overall the company emphasized long-term pipeline value and raised guidance despite near-term charges and select clinical setbacks.View all MRK earnings summariesMRK Sales Breakdown
89.43% Pharmaceutical
9.77% Animal Health
0.79% Other
MRK Stock 12 Month Forecast
Average Price Target
$136.50
▲(14.64% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
21.06% Mutual Funds
3.55% Other Institutional Investors
50.44% Public Companies and Individual Investors